CHEMM ChemoMetec

Notification of managers’ transactions

Notification of managers’ transactions

ANNOUNCEMENT NO. 244

14 September 2023



Notification of managers’ transactions



ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.

See the transactions of CEO Rasmus Kofoed in the attached PDF document.



For further information, please contact:

Niels Høy Nielsen, CFO

Telephone (+45) 2551 8724



About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.

ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to .

Attachment



EN
14/09/2023

Underlying

CHEMMChemoMetec

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ChemoMetec

 PRESS RELEASE
Free
CHEMM CHEMOMETEC

ChemoMetec enters Letter of Intent with Roche Diagnostics

ChemoMetec enters Letter of Intent with Roche Diagnostics ANNOUNCEMENT NO. 300 – IN ENGLISH ONLY 4 February 2026 ChemoMetec enters Letter of Intent with Roche Diagnostics ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating synergies between the parties’ technologies in the field of bioprocess monitoring. Over the course of 2026 the parties intend to explore and solidify initial ideas of combining the parties’ technologies into validated solutions in the field of bioprocess monitoring, starting with developing a co...

February 4, 2026 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

ChemoMetec enters Letter of Intent with Roche Diagnostics

ChemoMetec enters Letter of Intent with Roche Diagnostics ANNOUNCEMENT NO. 300 4 February 2026 ChemoMetec enters Letter of Intent with Roche Diagnostics ChemoMetec has entered a Letter of Intent with Roche Diagnostics aiming to pursue a collaboration with the goal of creating synergies between the parties’ technologies in the field of bioprocess monitoring. Over the course of 2026 the parties intend to explore and solidify initial ideas of combining the parties’ technologies into validated solutions in the field of bioprocess monitoring, starting with developing a connectivity of Chem...

February 4, 2026 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

1. halvår 2025/26 - Organisk vækst trods udfordringer på det nordameri...

1. halvår 2025/26 - Organisk vækst trods udfordringer på det nordamerikanske marked MEDDELELSE NR. 299 4. februar 2026 Delårsrapport for første halvår 2025/26 Organisk vækst trods udfordringer på det nordamerikanske marked Martin Helbo Behrens, CEO: I 1. halvår steg vores omsætning målt i lokale valutaer med 3%, mens den i danske kroner var på DKK 249,0 mio., svarende til et fald på 1% i forhold til samme periode sidste år. Trods dette viste driftsresultatet (EBITDA) og EBITDA-marginen en mindre stigning. Omsætningen var påvirket af en brat opbremsning i efterspørgslen i USA. Det skyl...

February 4, 2026 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Interim report 2025/26 - Organic growth despite challenges in the Nort...

Interim report 2025/26 - Organic growth despite challenges in the North American market ANNOUNCEMENT NO. 299 4 February 2026 Interim report for the first half of 2025/26         Organic growth despite challenges in the North American market Martin Helbo Behrens, CEO: In the first half of 2025/26, our revenue was up 3% measured in local currencies, while in Danish kroner it was down to DKK 249.0 million, a year-on-year decrease of 1%. Despite this, EBITDA and the EBITDA margin showed a slight increase. Revenue was affected by a sharp slowdown in US demand, as many of our customers in t...

February 4, 2026 1 EN
Free Trial
CHEMM CHEMOMETEC

ChemoMetec A S: 2 directors

Two Directors at ChemoMetec A S bought 1,817 shares at between 684.000DKK and 704.000DKK. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...

11/07/25 November 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch